EMD Millipore Introduces New ProteoExtract® Kits for More Rapid and Effective Cytoskeleton and Associated Protein Enrichment

  • Enables enrichment of cytoskeleton-associated proteins in as little as 20 minutes
  • Maintains actin cytoskeleton and associated proteins in their native, adhered conformations
  • Significantly reduces background signal, while allowing for improved detection of low-abundance cytoskeleton-associated proteins

Billerica, MA—August 2, 2011 — EMD Millipore, the Life Science division of Merck KGaA  of Darmstadt, Germany, today announced the launch of two new ProteoExtract Kits that enable researchers to more rapidly and effectively enrich, isolate, and analyze the cytoskeleton and associated proteins.

The ProteoExtract Cytoskeleton Enrichment and Isolation kit (cat. # 17-10195) provides the necessary extraction buffers to quickly and selectively remove soluble cytoplasmic and nuclear protein fractions for downstream biochemical analysis including western blot and mass spectrometry. The assay is performed in as little as 20 minutes and foregoes the need for harsh buffers and centrifugation, thus retaining more of the native focal adhesion- and actin-associated proteins, as compared to traditional protein fractionation methods.  Vimentin and GAPDH antibodies are also included as markers for the cytoskeleton and cytosol, respectively, for western blot analysis.

The ProteoExtract Native Cytoskeleton Enrichment and Staining Kit (cat. # 17-10210) includes the necessary reagents to efficiently enrich, retain and visualize the cytoskeleton and associated proteins in their native, adhered conformations with the same gentle technique. The kit also includes labeled phalloidin and antibodies against vinculin and GAPDH as markers for visualization and co-localization of the actin cytoskeleton, focal adhesions, and cytosol for immunofluorescence analysis.

“The ProteoExtract kits overcome many of the problems experienced when analyzing the cytoskeleton and associated proteins,” describes Haizhen Liu, Ph.D., Senior Research Scientist, EMD Millipore.  “The kits increase the amount of recoverable, enriched cytoskeleton fraction, maintain the cytoskeleton and associated proteins in their native states, increase the ability to detect and study low abundance actin-associated proteins that are typically lost with harsher protein fractionation methods, and greatly reduces the background typically seen in immunofluorescence staining of whole cells.”

For more information on the ProteoExtract Cytoskeleton Enrichment Kits, please visit http://www.millipore.com/catalogue/item/17-10195  and  http://www.millipore.com/catalogue/item/17-10210.

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries an 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

Leslie Eisenberg (Feinstein Kean Healthcare)
Phone: +1 617 244 3872
Email: [email protected]